{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T23:43:08Z","timestamp":1769730188638,"version":"3.49.0"},"reference-count":108,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["bprch.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice &amp; Research Clinical Haematology"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.beha.2017.11.003","type":"journal-article","created":{"date-parts":[[2017,11,20]],"date-time":"2017-11-20T04:00:31Z","timestamp":1511150431000},"page":"41-48","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Novel agents for relapsed and refractory follicular lymphoma"],"prefix":"10.1016","volume":"31","author":[{"given":"Chan Yoon","family":"Cheah","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathan H.","family":"Fowler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.beha.2017.11.003_bib1","series-title":"Surveillance, epidemiology, and end results (SEER) program populations (1969-2011) national cancer Institute, DCCPS, surveillance research program, surveillance systems branch","author":"National Cancer Institute","year":"2013"},{"key":"10.1016\/j.beha.2017.11.003_bib2","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1200\/JCO.1986.4.10.1470","article-title":"Follicular lymphoma: prognostic factors for response and survival","volume":"4","author":"Gallagher","year":"1986","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beha.2017.11.003_bib3","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/bjh.13316","article-title":"A\u00a0population-based study of prognosis in advanced stage follicular lymphoma managed by watch and wait","volume":"169","author":"El-Galaly","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2017.11.003_bib4","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/leu.2014.251","article-title":"Follicular lymphoma in Sweden: nationwide improved survival in the rituximab era, particularly in elderly women: a Swedish Lymphoma Registry study","volume":"29","author":"Junlen","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2017.11.003_bib5","series-title":"NCCN guidelines version 1.2015","author":"National Comprehensive Cancer Network","year":"2015"},{"issue":"suppl 5","key":"10.1016\/j.beha.2017.11.003_bib6","doi-asserted-by":"crossref","first-page":"v83","DOI":"10.1093\/annonc\/mdw400","article-title":"Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"27","author":"Dreyling","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.beha.2017.11.003_bib7","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1080\/17474086.2017.1291339","article-title":"When to treat patients with relapsed follicular lymphoma","volume":"10","author":"Cheah","year":"2017","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.beha.2017.11.003_bib8","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1182\/blood.V90.6.2188","article-title":"IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma","volume":"90","author":"Maloney","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.beha.2017.11.003_bib9","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program","volume":"16","author":"McLaughlin","year":"1998","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beha.2017.11.003_bib10","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1200\/JCO.2006.06.4618","article-title":"Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study","volume":"25","author":"Herold","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beha.2017.11.003_bib11","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood-2004-08-3175","article-title":"CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma","volume":"105","author":"Marcus","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.beha.2017.11.003_bib12","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","article-title":"Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial","volume":"377","author":"Salles","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.beha.2017.11.003_bib13","doi-asserted-by":"crossref","first-page":"6248","DOI":"10.1158\/1078-0432.CCR-04-0850","article-title":"Enhancement of the antibody-dependent cellular cytotoxicity of low-fucose IgG1 Is independent of FcgammaRIIIa functional polymorphism","volume":"10","author":"Niwa","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.beha.2017.11.003_bib14","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1182\/blood-2009-06-225979","article-title":"Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity","volume":"115","author":"Mossner","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.beha.2017.11.003_bib15","doi-asserted-by":"crossref","first-page":"3482","DOI":"10.1182\/blood-2013-05-504043","article-title":"Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab","volume":"122","author":"Golay","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.beha.2017.11.003_bib16","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1200\/JCO.2012.46.9718","article-title":"Obinutuzumab (GA101) in patients with relapsed\/refractory indolent non-Hodgkin lymphoma: results from the phase II GAUGUIN study","volume":"31","author":"Salles","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beha.2017.11.003_bib17","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1182\/blood-2013-01-481341","article-title":"Obinutuzumab (GA101) plus CHOP or FC in relapsed\/refractory follicular lymphoma: results of the GAUDI study (BO21000)","volume":"122","author":"Radford","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.beha.2017.11.003_bib18","doi-asserted-by":"crossref","first-page":"3467","DOI":"10.1200\/JCO.2014.59.2139","article-title":"Randomized phase II trial comparing obinutuzumab (GA101) with rituximab in patients with relapsed CD20+ indolent B-Cell non-hodgkin lymphoma: final analysis of the GAUSS study","volume":"33","author":"Sehn","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beha.2017.11.003_bib19","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/S1470-2045(16)30097-3","article-title":"Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre phase 3 trial","volume":"17","author":"Sehn","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.beha.2017.11.003_bib20","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.615.615","article-title":"Obinutuzumab plus bendamustine followed by obinutuzumab maintenance prolongs overall survival compared with bendamustine alone in patients with rituximab-refractory indolent non-hodgkin lymphoma: updated results of the GADOLIN study","volume":"128","author":"Cheson","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.beha.2017.11.003_bib21","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.6.6","article-title":"Obinutuzumab-Based induction and maintenance prolongs progression-free survival (PFS) in patients with previously untreated follicular lymphoma: primary results of the randomized phase 3 GALLIUM study","volume":"128","author":"Marcus","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.beha.2017.11.003_bib22","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/bjh.12708","article-title":"Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.)","volume":"164","author":"Gandhi","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2017.11.003_bib23","doi-asserted-by":"crossref","first-page":"3999","DOI":"10.1002\/cncr.25983","article-title":"Treatment with lenalidomide modulates T-cell immunophenotype and cytokine production in patients with chronic lymphocytic leukemia","volume":"117","author":"Lee","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.beha.2017.11.003_bib24","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/imm.12087","article-title":"Enhanced cross-priming of naive CD8+ T cells by dendritic cells treated by the IMiDs(R) immunomodulatory compounds lenalidomide and pomalidomide","volume":"139","author":"Henry","year":"2013","journal-title":"Immunology"},{"key":"10.1016\/j.beha.2017.11.003_bib25","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1182\/blood-2012-02-411678","article-title":"Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer","volume":"120","author":"Ramsay","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.beha.2017.11.003_bib26","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.exphem.2013.10.007","article-title":"Endothelium-mediated survival of leukemic cells and angiogenesis-related factors are affected by lenalidomide treatment in chronic lymphocytic leukemia","volume":"42","author":"Maffei","year":"2014","journal-title":"Exp Hematol"},{"key":"10.1016\/j.beha.2017.11.003_bib27","doi-asserted-by":"crossref","first-page":"5404","DOI":"10.1200\/JCO.2008.21.1169","article-title":"Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-hodgkin's lymphoma","volume":"27","author":"Witzig","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beha.2017.11.003_bib28","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/ajh.21468","article-title":"Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in\u00a0vitro and in\u00a0vivo","volume":"84","author":"Zhang","year":"2009","journal-title":"Am J Hematol"},{"key":"10.1016\/j.beha.2017.11.003_bib29","doi-asserted-by":"crossref","first-page":"4650","DOI":"10.1158\/1078-0432.CCR-07-4405","article-title":"Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells","volume":"14","author":"Wu","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.beha.2017.11.003_bib30","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/S1470-2045(14)70455-3","article-title":"Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial","volume":"15","author":"Fowler","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.beha.2017.11.003_bib31","doi-asserted-by":"crossref","first-page":"e454","DOI":"10.3324\/haematol.2015.131144","article-title":"Characteristics and management of rash following lenalidomide and rituximab in patients with untreated indolent non-Hodgkin lymphoma","volume":"100","author":"Fowler","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.beha.2017.11.003_bib32","article-title":"Activity of the immunologic doublet of lenalidomide plus obinutuzumab in relapsed follicular lymphoma: results of a phase I\/II study","volume":"35","author":"Fowler","year":"2017","journal-title":"J\u00a0Clin Oncol Meet Abstr"},{"key":"10.1016\/j.beha.2017.11.003_bib33","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/nrd4204","article-title":"PI3K and cancer: lessons, challenges and opportunities","volume":"13","author":"Fruman","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.beha.2017.11.003_bib34","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1182\/blood-2013-11-538546","article-title":"Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-delta, as therapy for previously treated indolent non-Hodgkin lymphoma","volume":"123","author":"Flinn","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.beha.2017.11.003_bib35","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","article-title":"PI3K\u03b4 inhibition by idelalisib in patients with relapsed indolent lymphoma","volume":"370","author":"Gopal","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beha.2017.11.003_bib36","first-page":"3037","article-title":"Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapy","volume":"22","author":"Gopal","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.beha.2017.11.003_bib37","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1097\/PAS.0000000000000522","article-title":"Idelalisib-associated colitis: histologic findings in 14 patients","volume":"39","author":"Weidner","year":"2015","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.beha.2017.11.003_bib38","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1182\/blood-2016-02-702761","article-title":"Idelalisib in the management of lymphoma","volume":"128","author":"Cheah","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.beha.2017.11.003_bib39","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1183\/13993003.01670-2015","article-title":"Idelalisib-related pneumonitis","volume":"47","author":"Haustraete","year":"2016","journal-title":"Eur Respir J"},{"key":"10.1016\/j.beha.2017.11.003_bib40","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1182\/blood-2016-03-707133","article-title":"Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity","volume":"14","author":"Lampson","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.beha.2017.11.003_bib41","series-title":"Idelalisib urgent safety letter","author":"Gilead Sciences Inc","year":"2016"},{"key":"10.1016\/j.beha.2017.11.003_bib42","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.3705.3705","article-title":"A\u00a0retrospective analysis of <em>Pneumocystis jirovecii<\/em> pneumonia infection in patients receiving idelalisib in clinical trials","volume":"128","author":"Sehn","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.beha.2017.11.003_bib43","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.5583.5583","article-title":"Temporal profiles of lymphocyte subsets and the correlation with infectious events in idelalisib-treated patients","volume":"128","author":"Sharman","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.beha.2017.11.003_bib44","doi-asserted-by":"crossref","first-page":"3357","DOI":"10.1182\/blood-2015-03-633156","article-title":"Lenalidomide, idelalisib, and rituximab are unacceptably toxic in patients with relapsed\/refractory indolent lymphoma","volume":"125","author":"Cheah","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.beha.2017.11.003_bib45","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1182\/blood-2013-11-535047","article-title":"Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110delta, for relapsed\/refractory chronic lymphocytic leukemia","volume":"123","author":"Brown","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.beha.2017.11.003_bib46","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa1315226","article-title":"Idelalisib and rituximab in relapsed chronic lymphocytic leukemia","volume":"370","author":"Furman","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beha.2017.11.003_bib47","article-title":"Copanlisib in patients with relapsed or refractory follicular lymphoma","volume":"35","author":"Dreyling","year":"2017","journal-title":"J\u00a0Clin Oncol Meet Abstr"},{"key":"10.1016\/j.beha.2017.11.003_bib48","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/hon.2437_57","article-title":"Dynamo: a phase 2 study demonstrating the clinical activity of duvelisib in patients with double-refractory indolent non-hodgkin lymphoma","volume":"35","author":"Zinzani","year":"2017","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.beha.2017.11.003_bib49","doi-asserted-by":"crossref","first-page":"13075","DOI":"10.1073\/pnas.1004594107","article-title":"The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy","volume":"107","author":"Honigberg","year":"2010","journal-title":"Proc Natl Acad Sci U. S. A"},{"key":"10.1016\/j.beha.2017.11.003_bib50","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1182\/blood-2011-10-386417","article-title":"The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in\u00a0vitro and in\u00a0vivo","volume":"119","author":"Ponader","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.beha.2017.11.003_bib51","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.clim.2011.12.009","article-title":"Defects in acute responses to TLR4 in Btk-deficient mice result in impaired dendritic cell-induced IFN-gamma production by natural killer cells","volume":"142","author":"Ni Gabhann","year":"2012","journal-title":"Clin Immunol"},{"key":"10.1016\/j.beha.2017.11.003_bib52","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1200\/JCO.2012.42.7906","article-title":"Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed\/refractory B-cell malignancies","volume":"31","author":"Advani","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beha.2017.11.003_bib53","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beha.2017.11.003_bib54","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1400376","article-title":"Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia","volume":"371","author":"Byrd","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beha.2017.11.003_bib55","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1501548","article-title":"Ibrutinib in previously treated Waldenstrom's macroglobulinemia","volume":"372","author":"Treon","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beha.2017.11.003_bib56","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beha.2017.11.003_bib57","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/S0140-6736(15)00667-4","article-title":"Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study","volume":"38","author":"Dreyling","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.beha.2017.11.003_bib58","article-title":"The Bruton's tyrosine kinase inhibitor ibrutinib (PCI-32765) is active and tolerated in relapsed follicular lymphoma","volume":"120","author":"Fowler","year":"2012","journal-title":"ASH Annu Meet Abstr"},{"key":"10.1016\/j.beha.2017.11.003_bib59","article-title":"Ibrutinib monotherapy in relapsed\/refractory follicular lymphoma (FL): preliminary results of a phase 2 consortium (P2C)","volume":"124","author":"Bartlett","year":"2014","journal-title":"Trial Blood ASH Annu Meet Abstr"},{"key":"10.1016\/j.beha.2017.11.003_bib60","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.1217.1217","article-title":"Ibrutinib as treatment for chemoimmunotherapy-resistant patients with follicular lymphoma: first results from the open-label, multicenter, phase 2 DAWN study","volume":"128","author":"Gopal","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.beha.2017.11.003_bib61","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.470.470","article-title":"Ibrutinib plus rituximab in treatment-naive patients with follicular lymphoma: results from a multicenter, phase 2 study","volume":"126","author":"Fowler","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.beha.2017.11.003_bib62","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1509981","article-title":"Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia","volume":"374","author":"Byrd","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beha.2017.11.003_bib63","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.832.832","article-title":"The BTK inhibitor, Bgb-3111, is safe, tolerable, and highly active in patients with relapsed\/refractory B-Cell malignancies: initial report of a phase 1 first-in-human trial","volume":"126","author":"Tam","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.beha.2017.11.003_bib64","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.3328.3328","article-title":"The Bruton's tyrosine kinase (BTK) inhibitor ONO-4059: promising single agent activity and well tolerated in patients with high risk chronic lymphocytic leukaemia (CLL)","volume":"124","author":"Fegan","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.beha.2017.11.003_bib65","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1124\/jpet.113.203489","article-title":"Inhibition of Btk with CC-292 provides early pharmacodynamic assessment of activity in mice and humans","volume":"346","author":"Evans","year":"2013","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.beha.2017.11.003_bib66","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0092-8674(04)00046-7","article-title":"Cell death: critical control points","volume":"116","author":"Danial","year":"2004","journal-title":"Cell"},{"key":"10.1016\/j.beha.2017.11.003_bib67","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.molcel.2011.10.001","article-title":"A\u00a0unified model of mammalian BCL-2 protein family interactions at the mitochondria","volume":"44","author":"Llambi","year":"2011","journal-title":"Mol Cell"},{"key":"10.1016\/j.beha.2017.11.003_bib68","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1200\/JCO.2011.34.7898","article-title":"Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease","volume":"30","author":"Roberts","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beha.2017.11.003_bib69","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"Souers","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.beha.2017.11.003_bib70","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","article-title":"Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-hodgkin lymphoma","volume":"35","author":"Davids","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beha.2017.11.003_bib71","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.255.255","article-title":"A\u00a0dose-escalation study of venetoclax (ABT-199\/GDC-0199) in combination with bendamustine and rituximab in patients with relapsed or refractory non-hodgkin's lymphoma","volume":"126","author":"de Vos","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.beha.2017.11.003_bib72","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1200\/JCO.2009.25.1900","article-title":"Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study","volume":"28","author":"Advani","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beha.2017.11.003_bib73","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1111\/j.1349-7006.2012.02241.x","article-title":"Phase I study of anti-CD22 immunoconjugate inotuzumab ozogamicin plus rituximab in relapsed\/refractory B-cell non-Hodgkin lymphoma","volume":"103","author":"Ogura","year":"2012","journal-title":"Cancer Sci"},{"key":"10.1016\/j.beha.2017.11.003_bib74","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1200\/JCO.2012.42.7211","article-title":"Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I\/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab","volume":"31","author":"Fayad","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beha.2017.11.003_bib75","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/S1470-2045(15)70128-2","article-title":"Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study","volume":"16","author":"Palanca-Wessels","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.beha.2017.11.003_bib76","first-page":"177","article-title":"Two doses of polatuzumab vedotin in patients with relapsed\/refractory follicular lymphoma: durable responses at lower dose","volume":"33","author":"Sharman","year":"2015","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.beha.2017.11.003_bib77","first-page":"769","article-title":"Anticancer activities of histone deacetylase inhibitors","volume":"5","author":"Bolden","year":"2006","journal-title":"Nat Rev"},{"key":"10.1016\/j.beha.2017.11.003_bib78","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/nature02625","article-title":"Epigenetics in human disease and prospects for epigenetic therapy","volume":"429","author":"Egger","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.beha.2017.11.003_bib79","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1586\/14737140.7.10.1439","article-title":"Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agents","volume":"7","author":"Bishton","year":"2007","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.beha.2017.11.003_bib80","doi-asserted-by":"crossref","first-page":"4636","DOI":"10.1182\/blood-2003-09-3068","article-title":"T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance","volume":"103","author":"Piekarz","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.beha.2017.11.003_bib81","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1200\/JCO.2014.59.2782","article-title":"Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: results of the pivotal phase II BELIEF (CLN-19)","volume":"33","author":"O'Connor","year":"2015","journal-title":"Study J Clin Oncol"},{"key":"10.1016\/j.beha.2017.11.003_bib82","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.2006.10.2434","article-title":"Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma","volume":"25","author":"Olsen","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beha.2017.11.003_bib83","doi-asserted-by":"crossref","first-page":"5827","DOI":"10.1182\/blood-2010-10-312603","article-title":"Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma","volume":"117","author":"Piekarz","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.beha.2017.11.003_bib84","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1200\/JCO.2010.32.1398","article-title":"Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma","volume":"29","author":"Kirschbaum","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beha.2017.11.003_bib85","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1111\/bjh.12819","article-title":"A\u00a0multicentre phase II study of vorinostat in patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma","volume":"165","author":"Ogura","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2017.11.003_bib86","doi-asserted-by":"crossref","first-page":"357","DOI":"10.3324\/haematol.2014.117473","article-title":"A\u00a0phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed\/refractory indolent non-Hodgkin lymphoma","volume":"100","author":"Chen","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.beha.2017.11.003_bib87","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1016\/j.ejca.2013.05.009","article-title":"Pharmacokinetic\/pharmacodynamic modelling-based optimisation of administration schedule for the histone deacetylase inhibitor abexinostat (S78454\/PCI-24781) in phase I","volume":"49","author":"Fouliard","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.beha.2017.11.003_bib88","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1158\/1078-0432.CCR-15-0624","article-title":"A\u00a0phase I\/II multicenter, open-label study of the oral histone deacetylase inhibitor abexinostat in relapsed\/refractory lymphoma","volume":"22","author":"Evens","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.beha.2017.11.003_bib89","doi-asserted-by":"crossref","first-page":"20980","DOI":"10.1073\/pnas.1012525107","article-title":"Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas","volume":"107","author":"Sneeringer","year":"2010","journal-title":"Proc Natl Acad Sci U. S. A"},{"key":"10.1016\/j.beha.2017.11.003_bib90","doi-asserted-by":"crossref","first-page":"3879","DOI":"10.1073\/pnas.1121343109","article-title":"Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing","volume":"109","author":"Lohr","year":"2012","journal-title":"Proc Natl Acad Sci U. S. A"},{"key":"10.1016\/j.beha.2017.11.003_bib91","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1158\/1535-7163.MCT-13-0773","article-title":"Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma","volume":"13","author":"Knutson","year":"2014","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.beha.2017.11.003_bib92","first-page":"179","article-title":"Phase I study of E7438 (EPZ-6438), an enhancer of Zeste-homolog 2 (EZH2) inhibitor: dose determination and preliminary activity in non-Hodgkin lymphoma","volume":"33","author":"Ribrag","year":"2015","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.beha.2017.11.003_bib93","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","article-title":"Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation","volume":"192","author":"Freeman","year":"2000","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.beha.2017.11.003_bib94","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1074-7613(00)80089-8","article-title":"Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor","volume":"11","author":"Nishimura","year":"1999","journal-title":"Immunity"},{"key":"10.1016\/j.beha.2017.11.003_bib95","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.imlet.2005.09.007","article-title":"Co-inhibitory role of T-cell-associated B7-H1 and B7-DC in the T-cell immune response","volume":"102","author":"Seo","year":"2006","journal-title":"Immunol Lett"},{"key":"10.1016\/j.beha.2017.11.003_bib96","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1084\/jem.20090847","article-title":"PD-L1 regulates the development, maintenance, and function of induced regulatory T cells","volume":"206","author":"Francisco","year":"2009","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.beha.2017.11.003_bib97","doi-asserted-by":"crossref","first-page":"5393","DOI":"10.1158\/0008-5472.CAN-11-0993","article-title":"IL-18 induces PD-1-dependent immunosuppression in cancer","volume":"71","author":"Terme","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.beha.2017.11.003_bib98","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1182\/blood-2008-12-195792","article-title":"Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired","volume":"114","author":"Ahmadzadeh","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.beha.2017.11.003_bib99","doi-asserted-by":"crossref","first-page":"12293","DOI":"10.1073\/pnas.192461099","article-title":"Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade","volume":"99","author":"Iwai","year":"2002","journal-title":"Proc Natl Acad Sci U. S. A"},{"key":"10.1016\/j.beha.2017.11.003_bib100","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1200\/JCO.2009.26.7609","article-title":"Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates","volume":"28","author":"Brahmer","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beha.2017.11.003_bib101","doi-asserted-by":"crossref","first-page":"4311","DOI":"10.1200\/JCO.2013.51.4802","article-title":"Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma","volume":"31","author":"Weber","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beha.2017.11.003_bib102","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study","volume":"34","author":"Lesokhin","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beha.2017.11.003_bib103","article-title":"Response rates with pembrolizumab in combination with rituximab in patients with relapsed follicular lymphoma: interim results of an on open-label, phase II study","volume":"35","author":"Nastoupil","year":"2017","journal-title":"J\u00a0Clin Oncol Meet Abstr"},{"key":"10.1016\/j.beha.2017.11.003_bib104","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beha.2017.11.003_bib105","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beha.2017.11.003_bib106","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1200\/JCO.2014.56.2025","article-title":"Chemotherapy-refractory diffuse large B-Cell lymphoma and indolent B-Cell malignancies can Be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor","volume":"33","author":"Kochenderfer","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beha.2017.11.003_bib107","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.183.183","article-title":"Sustained remissions following chimeric antigen receptor modified T cells directed against CD19 (CTL019) in patients with relapsed or refractory CD19+ lymphomas","volume":"126","author":"Schuster","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.beha.2017.11.003_bib108","article-title":"Anti-CD19 chimeric antigen receptor-modified T cell Therapy for B Cell non-hodgkin lymphoma and chronic lymphocytic leukemia: fludarabine and cyclophosphamide lymphodepletion improves in\u00a0vivo expansion and persistence of CAR-T cells and clinical outcomes","volume":"126","author":"Turtle","year":"2015","journal-title":"Blood"}],"container-title":["Best Practice &amp; Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692617300804?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692617300804?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,22]],"date-time":"2020-10-22T03:57:13Z","timestamp":1603339033000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692617300804"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":108,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["S1521692617300804"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2017.11.003","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel agents for relapsed and refractory follicular lymphoma","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2017.11.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}